Company & Sponsor Intelligence
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials2
Recruiting0
Completed2
Countries0
Therapeutic footprint
alzheimersepilepsy
Indexed studies
NCT00034762Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease
alzheimers · PHASE3
alzheimers · PHASE3
NCT01060228A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy Men
epilepsy · PHASE1
epilepsy · PHASE1
NCT00253214Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation
alzheimers · PHASE3
alzheimers · PHASE3
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →